Skip to navigation Skip to main content
Oncology Nurse Advisor
  • Cancer Types
    • Cancer Types
      • Brain Cancer
      • Breast Cancer
      • Cervical Cancer
      • Chronic Myeloid Leukemia‎
      • Colorectal Cancer
      • Gastrointestinal Cancer
      • General Oncology
      • Genitourinary Cancer
      • Gynecologic Cancer
      • Head and Neck Cancer
      • Hematologic Cancers
      • Kidney Cancer
      • Leukemia
      • Liver Cancer
      • Lung Cancer
      • Lymphoma
      • Melanoma
      • Multiple Myeloma
      • Myeloproliferative Neoplasms
      • Ovarian Cancer
      • Pancreatic Cancer
      • Prostate Cancer
      • Sarcoma
      • Skin Cancer
  • Hot Topics
    • Hot Topics
      • Advisor Forum
      • Ask a Pharmacist
      • Ask the Experts
      • Communication Challenges
      • Complementary and Alternative Medicine
      • From CancerCare
      • General Medicine
      • Issues in Cancer Survivorship
      • Journal Review
      • Navigation
      • Oncology Nursing
      • Radiation and Your Patient
      • Reflections
      • Side-Effect Management
      • Stat Consult
      • The Patient’s Voice
      • The Total Patient
  • Resources
    • Resources

      Clinical Tools

      • Clinical Charts
      • Drug Information Database
      • Medical Calculators

      Professional Resources

      • Expert Perspective
      • Digital Issues
      • Job Board
      • Product Directory
      • Useful Links
  • For Patients
    • For Patients
      • Advocacy
      • Cancer Support Groups
      • Fact Sheets
      • Finding Clinical Trials
  • Conferences
    • Conferences

      Oncology Conferences

      • Conference Coverage

      News Resources

      • Daily Oncology News
      • Web Exclusives
  • ONA Summit
  • News
  • CE
  • Fact Sheets
  • Publishers Alliance
  • Navigation
  • Expert Perspective
  • Slideshows
  • Jobs

Home » Headlines

Publish Date October 7, 2015

Chemotherapy Use Associated with Survival Benefit Among Medicare Patients with SCLC

  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share on Reddit
  • Print
  • Share by Email

the Oncology Nurse Advisor take:

Chemotherapy use was associated with a survival benefit for Medicare patients with small cell lung cancer (SCLC) treated in a real-world setting, a new study published online ahead of print in the journal Cancer has shown.

Because there have been limited therapeutic advances in the management of SCLC over the last three decades, researchers led by Madhusmita Behera, PhD, from the Department of Hematology and Medical Oncology at Emory University in Atlanta, Georgia, sought to evaluate real-world trends in the use of systemic therapies and the impact on patient outcomes among patients with SCLC in the United States.

For the study, researchers analyzed data from 47,351 patients with SCLC diagnosed between 1985 and 2005 from the Surveillance, Epidemiology, and End Results (SEER)–Medicare database. Among them, 52% were male, 87% were white, 7% were black, and 1.4% was Asian.

Results showed that the proportion of patients treated with chemotherapy increased from 38% between 1985 and 1990 to 53% between 2001 and 2005. Researchers found that females, Asians, and rural residents were more likely to receive chemotherapy.

In regard to survival benefit with chemotherapy, the median overall survival with and without chemotherapy was 9.6 months and 3.6 months, respectively.

The study demonstrated no survival difference between patients treated with carboplatin and patients treated with cisplatin; however, additional therapy beyond platinum-based chemotherapy was associated with a survival benefit.

Chemotherapy use associated with a survival benefit for Medicare patients with small cell lung cancer (SCLC) treated in a real-world setting.

Behera, M., Ragin, C., Kim, S., Pillai, R. N., Chen, Z., Steuer, C. E., Saba, N. F., Belani, C. P., Khuri, F. R., Ramalingam, S. S. and Owonikoko, T. K. (2015), Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer.

READ FULL ARTICLE Curated publisher From Wiley Online Library

Topics:

Lung Cancer Small Cell Lung Cancer
  • Loading...

  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More

Next post in Headlines
Mutated genes in leukemia can reprogram blood stem cells, affecting blood cell production.

Patient-Reported Physical Functioning May Predict HCT Outcomes

Back to Top
  • Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community online and in print. Daily online exclusives cover late breaking oncology news, safe handling and administration of chemotherapy drugs, side effect management, and new developments in specific cancers.

  • Resources
    • Editorial Board
    • Subscribe
    • Author Guidelines
    • Permissions
    • Reprints
  • User Center
    • About Us
    • Contact Us
    • Advertise
  • Other Haymarket Medical Websites
    • Cancer Therapy Advisor
    • Clinical Advisor
    • Clinical Pain Advisor
    • Dermatology Advisor
    • Endocrinology Advisor
    • Gastroenterology Advisor
    • Hematology Advisor
    • Infectious Disease Advisor
    • McKnight’s Long Term Care News
    • McKnight’s Senior Living
    • Medical Bag
    • MPR
    • myCME
    • Neurology Advisor
    • Ophthalmology Advisor
    • Optometry Advisor
    • Psychiatry Advisor
    • Pulmonology Advisor
    • Rare Disease Advisor
    • Renal and Urology News
    • Rheumatology Advisor
    • The Cardiology Advisor
  • Copyright © 2023 Haymarket Media, Inc. All Rights Reserved
    This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.
    Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions.

Loading...
Loading...
Loading...
Loading...